Regeneus Ltd Stock Australian S.E.

Regeneus Ltd is an Australia-based clinical-stage regenerative medicine company. The Company uses stem cell technologies to develop a portfolio of novel cell-based therapies. The Company develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.